Validity of laboratory-based surveillance for detection of respiratory syncytial virus seasons

American Journal of Epidemiology

Volumn 177, Issue 8, 2013, Pages 841-851

  Hampp, Christian ^a   Asal, Nabih ^a   Lipowski, Earlene ^a   Kauf, Teresa ^a   Schneider, Eileen ^a   Kubilis, Paul ^a   Winterstein, Almut ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

immunoprophylaxis; Medicaid; palivizumab; pediatrics; respiratory syncytial virus; seasonality; validity

Indexed keywords

PALIVIZUMAB;

DETECTION METHOD; DISEASE INCIDENCE; HEALTH EXPENDITURE; HEALTH RISK; HOSPITAL SECTOR; RESPIRATORY DISEASE; SEASONALITY; VIRUS;

ACCURACY; ANTIVIRAL THERAPY; ARTICLE; BIRTH; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; GEOGRAPHIC DISTRIBUTION; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAID; PNEUMOVIRUS INFECTION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEASONAL VARIATION; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CALIFORNIA; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DISEASE OUTBREAKS; FEMALE; FLORIDA; HUMANS; ILLINOIS; INCIDENCE; INFANT; INSURANCE, HOSPITALIZATION; LABORATORIES; MALE; MEDICAID; PREVALENCE; REPRODUCIBILITY OF RESULTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; ROC CURVE; SEASONS; SENTINEL SURVEILLANCE; TEXAS; UNITED STATES;

CALIFORNIA; FLORIDA [UNITED STATES]; ILLINOIS; TEXAS; UNITED STATES;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84876243570     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws304     Document Type: Article

References (35)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl JMed. 2009;360(6):588-598.
2. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446.
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537.
4. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93-99.
5. Hampp C, Kauf TL, Saidi AS, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498-505.
6. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics:the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003;22(2 suppl):S21-S32.
7. Mullins JA, Lamonte AC, Bresee JS, et al. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J. 2003;22(10):857-862.
8. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks:lessons from national surveillance. Pediatr Infect Dis J. 2007;26(11 suppl):S41-S45.
9. Centers for Disease Control and Prevention. Respiratory syncytial virus\-United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep. 2011;60(35):1203-1206.
10. Light M. Respiratory syncytial virus seasonality in southeast Florida:results from three area hospitals caring for children. Pediatr Infect Dis J. 2007;26(11 suppl):S55-S59.
11. Meissner HC. Summary. Pediatr Infect Dis J. 2011; 26(11 suppl):S60.
12. Bauman J, Eggleston M, Oquist N, et al. Respiratory syncytial virus:seasonal data for regions of Florida and implications for palivizumab. South Med J. 2007; 100(7):669-676.
13. Fergie J, Purcell K. Respiratory syncytial virus laboratory surveillance and hospitalization trends in South Texas. Pediatr Infect Dis J. 2007;26(11 suppl):S51-S54.
14. Gilchrist S, Török TJ, Gary HE Jr, et al. National surveillance for respiratory syncytial virus, United States, 1985-1990. JInfect Dis. 1994;170(4):986-990.
15. Halstead DC, Jenkins SG. Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States. South Med J. 1998;91(5):433-436.
16. Light M, Bauman J, Mavunda K, et al. Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida. Pediatr Infect Dis J. 2008;27(6):512-518.
17. Meerhoff TJ, Paget JW, Kimpen JL, et al. Variation of respiratory syncytial virus and the relation with meteorological factors in different winter seasons. Pediatr Infect Dis J. 2009;28(10):860-866.
18. Singleton RJ, Bruden D, Bulkow LR, et al. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Pediatr Infect Dis J. 2006;25(12):1116-1122.
19. Eworuke E, Hampp C, Saidi A, et al. An algorithm to identify preterm infants in administrative claims data. Pharmacoepidemiol Drug Saf. 2012;21(6):640-650.
20. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6):1442-1446.
21. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome:a novel risk factor for respiratory syncytial virus bronchiolitis\-a prospective birth-cohort study. Pediatrics. 2007;120(4):e1076-e1081.
22. Committee on Infectious Diseases. From the American Academy of Pediatrics:policy statements\-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124(6):1694-1701.
23. El Saleeby CM, Somes GW, De Vincenzo JP, et al. Risk factors for severe respiratory syncytial virus disease in children with cancer:the importance of lymphopenia and young age. Pediatrics. 2008;121(2):235-243.
24. Pohl C, Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):166-169.
25. Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2011;21(1):53-60.
26. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE):the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007;46(6):983-988.
27. Perneczky R, Pohl C, Sorg C, et al. Complex activities of daily living in mild cognitive impairment:conceptual and diagnostic issues. Age Ageing. 2006;35(3):240-245.
28. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction:the Framingham Heart Study. JAMA. 2002;288(10):1252-1259.
29. Gönen M. Receiver operating characteristic (ROC) curves. (Paper210-31). In:Proceedings of the Thirty-first Annual SAS Users Group International Conference. Cary, NC:SAS Institute Inc; 2006. (http://www2.sas. com/proceedings/sugi31/ 210-31.pdf). (Accessed October 17, 2011).
30. Panozzo CA, Stockman LJ, Curns AT, et al. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics. 2010;126(1):e116-e123.
31. Mood A, Graybill F, Boes D. Introduction to the Theory of Statistics. New York, NY:Mc Graw-Hill Publishing Company; 1974.
32. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY:Chapman & Hall, Inc; 1994.
33. Littell RC, Miliken GA, Stroup WW, et al. SASfor Mixed Models. Cary, NC:SAS Institute Inc; 2006.
34. Florida Department of Health. Respiratory Syncytial Virus. Tallahassee, FL:Florida Department of Health; 2009. (http:// www.doh.state.fl.us/disease- ctrl/epi/RSV/rsv.htm). (Accessed September 07, 2009).
35. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus:results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(8):511-517.